Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I've been rolling with Sidney & ALRT(F) since 2012. Love this PR, keep it coming!
Any insight to today's movement? Just logged onto my eTrade account for the first time today and spit my water out seeing that 300% gain.
Are we going to get any clarity on how our expert market sweetheart went from quiet time to almost a billion in forecasted revenue?
Trying not to get too excited over here.
How do you go to zero + expert markets when millions of doses of vaccines are being given globally and your product destroys needles?
This is incredibly frustrating for a LT holder.
I LOVE this move from ALRT. People go to pretty insane lengths to keep their pets healthy and to extend their lives (I get it, I'm just not one of those people). Folks will spend thousands on treatments, so adopting preventative measures to keep their little companions healthy should be a great draw. Well done, ALRT.
I could be wrong, but no capital gains taxes in Singapore. Market traction, strong target market in-region, and potential to maximize gains from an exit event for the company...
I don't see the local culture element as a negative... If it's an option that local medicine points patients to, why not support it? Build trust in the platform for a volume of patients.
The previous q3 report from February was only the balance sheet. Amended attorney letter also calls out that specific report being added. Guessing this gets them current this week.
They did add a footnote re: the float in that q3 report that was not included in the amended annual report from earlier.
“Public Float” shall mean the total number of unrestricted shares not held directly or indirectly by an officer, director, any person who is the beneficial owner of more than 10 percent of the total shares outstanding (a “control person”), or any affiliates thereof, or any immediate family members of officers, directors and control persons.
Much appreciated and agreed on the options to incentivize the staff. Really hoping we see some good news soon. We know that Mr Chan won't send out any fluff PR just because we haven't heard anything in a while. Fingers crossed we're close and there's good news worth sharing!
Am I reading these pieces in bold correctly as options for the company to buy back 29.5m shares?
Recent Developments – Subsequent to March 31, 2021
On April 12, 2021, the Company elected to extend the initial 90-day period (April 22, 2021) by an additional 100-day period from the closing of the Rights Offering. The Company has until July 31, 2021 to sell the remaining 113,025,592 shares of common stock.
On April 14, 2021, the Company’s Board of Directors approved the grant of options to acquire an aggregate 28,500,000 shares of common stock at a price of $0.05 per share until December 31, 2025. The options to acquire shares will vest according to performance or time-based conditions and none of these options granted had vested as of the date of this report.
The Company entered into two Debt Settlement Agreements whereby the Company has agreed to issue an aggregate of 4,400,000 shares of common stock to two creditors of the Company to extinguish $194,186 in accounts payable and $23,000 in promissory notes and interest. The shares were issued on May 10, 2021. The Company also issued commitment letters to two creditors offering them an aggregate of 20,000,000 shares of common stock in exchange for the extinguishment of $1,511,377 in promissory notes and interest payable prior to December 31, 2021.
On May 12, 2021, the Company’s Board of Directors approved the grant of the option to acquire an aggregate 1,000,000 shares of common stock at a price of $0.05 per share until December 31, 2025. The options to acquire shares will vest according to performance conditions, and none of these options granted had vested as of the date of this report.
Worth noting Dennis Tan was listed as the author on the annual report, too. Check the metadata on the report all the way at the bottom.
Not gonna lie, really wish I was seeing the SNDD device on the sidelines when I got doses one and two of Pfizer last month... SNDD PRO should be at every vaccination location!
They were current yesterday and the next round of filings aren't due until the 15th, right?
Wouldn't that almost guarantee this is a format issue? Not sure what else it could be based on those two facts.
Might be some great buying opportunities today, folks.
I've seen bits and pieces of this posted on Twitter and ihub, but wanted to consolidate some timeline mentions of Chen Ren (Feiyang), TGGI, and Zuixiangui.
First mention of Ren Feiyang's Zuixiangui wine, May 2019 (https://www.guohuayule.com/zongyi/20190516/17501.html)
May 2019 is the first time Zuixiangui.com is indexed by Google.
June 2020 - Mention of reverse merger with US OTC (https://cn.chinadaily.com.cn/a/202006/22/WS5ef08bdda310a859d09d39b5.html) and (https://i.ifeng.com/c/7xVyDcOVWIS)
Sept 2020 - Ownership change of TGGI from Matt Dwyer to Chen Ren, annual report reflect changes.
January 2021 - Mention of TGGI, Ren Feiyang, OTC merger.
(https://mp.weixin.qq.com/s?src=11×tamp=1619660975&ver=3037&signature=7LrLzRYekpTuoxdPcJCw7fuxQHzg-VWGgyi8k3D1E1fsuZPkMHyXAeb66s-brMyHErubs1ZMZPbLyCAtWlZkWgWEecom4oB7YgXmQ4e7qS2CchKyAb2QSEDgFXAn7kKu&new=1)
March 2021 - Mention of Hong Kong Zuixiangui International Holdings being a subsidiary of TGGI.
(https://mp.weixin.qq.com/s?src=11×tamp=1619661339&ver=3037&signature=7LrLzRYekpTuoxdPcJCw7fuxQHzg-VWGgyi8k3D1E1caWbrj9AHf3ckROdl9PnRN3uT5BAc5tZGpRptQiefJdrICXoxTboNBtiIipHyoFaFn9wVYzv3pk3Ru*6KQM8p6&new=1)
April 2021 - Via translation - The Global Group is a U.S. OTC listed company with the stock code TGGI. The domestic headquarter is located in Shenzhen, Guangdong. It is a large group company focusing on the field of health and smart technology. Its business scope covers: capital operation section, international wine industry section, youth health section, women's health section, middle-aged and elderly health section, and biopharmaceuticals Sector, smart technology sector, internet sector, etc.
(https://www.sohu.com/a/462345365_120408780)
I think there's more out there, just takes a lot of trial and error translating and searching on sogou.
I did notice IGPK preferred shares were mentioned on TGGI's latest annual report. This was something from the Dwyer days of TGGI, not sure what the current status is, and if Chen will have any say over IGPK. Does anyone have any additional insight on that in addition to all the speculative DD about what's going on in China?
https://twitter.com/igpkotc/status/1381771758554992643?s=21
Very frustrated my order at 53 didn't get filled today. Going to try to add to my position anytime this is under 55. I think some updates are imminent. 10k today, OTCQB cert for 2020 as well.
I had originally submitted thinking the deadline was earlier this month, luckily eTrade was able to withdraw that so I could double the number today. Hoping for some good news in the coming weeks and really wish I could have exercised 100% of my options instead of what I was able to do.
I'm surprised a med software company isn't gaining more traction right now with the recent PRs. Especially since ALRT has never been a company to post fluff pieces... All this is pointing to revenue in the coming months. For the points mentioned earlier, Canada represents a massive opportunity. Very exciting!
This right here:
ALRT is offering its turnkey diabetes management solution at a cost that is far below competitors’ prices for hardware alone, giving ALRT a clear competitive advantage to rapidly capture market share. Doctors and Diabetes Singapore are incentivized to onboard patients, as they will receive a portion of the revenue generated from the subscriptions in addition to improving clinical outcomes.
Building in a revenue share with a very aggressive price point builds this thing for scale. Let's go.
This right here:
ALRT is offering its turnkey diabetes management solution at a cost that is far below competitors’ prices for hardware alone, giving ALRT a clear competitive advantage to rapidly capture market share. Doctors and Diabetes Singapore are incentivized to onboard patients, as they will receive a portion of the revenue generated from the subscriptions in addition to improving clinical outcomes.
Building in a revenue share with a very aggressive price point builds this thing for scale. Let's go.
Not planning on seeing anything soon since we're not halfway into it yet. I am hoping that this thing runs hard in November off some good news tied back to this trial and what's going on overseas.
I think this is good news to show the kind of value these types of solutions have from an acquisition perspective. As soon as ALRT starts to generate some revenue it should catch on like wildfire, especially with what's going on in the world right now. Telemedicine and remote care is here to stay even after we get through this pandemic and I would anticipate healthcare regulation making it easier to provide remote care, so solutions that help proactively manage patients remotely will be a massive value to healthcare providers. A higher volume of patients can be managed more efficiently by the clinician and the related admin overhead element should decrease, as well.
Drives me nuts that we see a strong PR when the company has a track record of not providing fluff to generate interest, followed by a spike in volume and a pullback to the normal volume within 24 hours.
Seems like this thing should be running, but looking forward to some positive news tied to more deals getting signed from these trials. The prediabetes solution is big-time news, and very valuable to help drive better patient outcomes with significant cost avoidance and lower overhead tied clinicians and admin.
Uplisting to OTCQB from OTCPink?
I recall this being mentioned, but what are the potential benefits of this for us shareholders?
https://backend.otcmarkets.com/otcapi/company/financial-report/244347/content
Agree. Every time I've emailed to him about PR and discussing deals he would always reiterate that he would only issue PR when there was something to report on, same goes for any "deals" that he was working on rather than just push PR fluff at any opportunity. I would bet that there has to be something in queue. Here's to hoping something pops. My youngest shares turn 1 on the 23rd, so this could be some nice timing.
It would be great if they were working on some content related to these website updates. Demo of the platform working with some of the outlined devices. User experience logging into the online portal.
I did notice that the two "active" networks listed on the portal log-in were United States and Chile. Thought that was interesting considering where they've been seeing success from a PR perspective (India, Middle East, Canada). You'd assume they'd have patient data localized to those regions, thus having active networks available in those areas, not the two listed.
Interesting activity...
So @BioAlberta is Alberta's Association for the Life Science Industries...
Can't help but notice that by 2025, an estimated 430k+ Albertans will be living with diabetes.
Pretty clear that ALRT is working on some stuff in Canada and won't announce anything until it's official. I really hope some news of partnership(s) coincides with or hits before the pending increase in common stock.
No. They adjusted the option to match the value of the stock in 2015. I'd want my strike price to match that value, too. Wish I had the option to acquire 500k @ that price right now.
ALRT DD
Spoke with the CEO yesterday, here are the cliffs:
They're targeting payers, primarily payers of last resort who are left with the check no matter what.
Focusing their value on the gap in proactive care to slow the affects of diabetes by addressing five causes of ineffective care:
1. Patient non-adherence to prescribed care plans;
2. Unreliable and inaccurate blood glucose data;
3. Time consuming to analyze reliable and accurate data, if available;
4. Failure to adjust care plans in a timely manner; and
5. Insulin dosing based on clinical judgement, not data
Showcasing why they're different (using patent pending predictive analytics) than other diabetes care providers and that it provides value at scale across the population.
Currently pursuing double digit initiatives outside the US, two of which are co-marketing opportunities with device manufacturers.
Overall, the reply seemed like a boilerplate response he's been sending folks inquiring about the company. He's been responsive and transparent every time I've emailed him, their go-to-market strategy seems calculated and well thought out. I've been long since 2012 and have doubled my position in the last few months. Optimistic about the future in this one.
Patience, a lot of patience. Just glad I was able to increase my position significantly two years ago. So far so good on the returns :).
Company mission hits close to home so I stuck with it longer than I do with other biotech and life science companies I've invested in (and I usually stay away from the OTC to be perfectly honest).
Here's to continued momentum.
It's really easy when you've been holding onto the stock for seven years!
Hoping we continue in this direction! Next two months should be positive.
Email from Sidney
I must say, after getting a response from Sidney Chan today I'm feeling much better about maintaining my long position on ALRT. I initially got in on 2012 and have added since. Tuesday's news was definitely a surprise, and the SEC filing portion of the 8k was troublesome, but once I received a direct response from him about these concerns I'm feeling positive about maintaining my position and holding out for what the technology/platform is capable of.
If he follows through on his plan to present their full diabetes platform within 45 days this company is going to explode.